Dapagliflozin patent?

What is the patent status of Dapagliflozin?

Dapagliflozin is an oral antidiabetic drug developed by AstraZeneca and Bristol Myers Squibb. The drug's patent status is a complex issue, with multiple patents held by the companies involved in its development.

Why are companies challenging this patent?

There have been concerns raised about the validity and enforcement of Dapagliflozin's patents, particularly in light of the patent expiration timelines. In 2020, AstraZeneca and Bristol Myers Squibb extended the Dapagliflozin patent through a settlement with other companies to maintain its market exclusivity [1]. However, this extension of patent protection has been met with resistance from generic manufacturers, who argue that it hampers competition and inflates prices for patients.

When does exclusivity expire?

The patent for Dapagliflozin is set to expire in various countries at different times. In the United States, the patent for the drug expired on February 20, 2027 [2]. In Europe, the patent expires in May 2027. However, generic versions of the drug were launched shortly after the patent expired in the United States. It remains to be seen when and how generic versions will be made available in other markets.

What happens if a generic version of Dapagliflozin enters the market?

If a generic version of Dapagliflozin were to enter the market, prices are expected to decline sharply. According to a study published in the Journal of Managed Care & Specialty Pharmacy, a generic version of the drug could lead to savings of up to 65% for patients [3]. This development would have significant implications for patients relying on this medication and could potentially disrupt the market share of the current manufacturers.

How does Dapagliflozin compare with other antidiabetic drugs?

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which works by increasing the excretion of glucose in the urine. In comparison to other antidiabetic drugs, Dapagliflozin has been shown to have a more rapid onset of action and improved glycemic control [4]. However, it also has a higher risk of adverse effects, including genitourinary infections and dehydration.

Sources:
[1] - https://www.drugpatentwatch.com/patent/US-20110156522
[2] - https://www.drugpatentwatch.com/patent/US-7763011
[3] - https://www.jmcp.org/doi/abs/10.18553/jmcp.2022.28.7.1047
[4] - https://pubmed.ncbi.nlm.nih.gov/29439821

Additional sources:

DrugPatentWatch.com - Dapagliflozin - 2027 Patent Expiration Date (February 20, 2027)

Patent expiry dates may be subject to change based on various factors, including court decisions or amendments to patent laws.